questionsmedicales.fr
Structures de l'embryon
Feuillets embryonnaires
Feuillets embryonnaires : Questions médicales fréquentes
Termes MeSH sélectionnés :
Early Detection of Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Feuillets embryonnaires : Questions médicales les plus fréquentes",
"headline": "Feuillets embryonnaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Feuillets embryonnaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-24",
"dateModified": "2025-04-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Feuillets embryonnaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Structures de l'embryon",
"url": "https://questionsmedicales.fr/mesh/D004628",
"about": {
"@type": "MedicalCondition",
"name": "Structures de l'embryon",
"code": {
"@type": "MedicalCode",
"code": "D004628",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A16"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Ectoderme",
"alternateName": "Ectoderm",
"url": "https://questionsmedicales.fr/mesh/D004475",
"about": {
"@type": "MedicalCondition",
"name": "Ectoderme",
"code": {
"@type": "MedicalCode",
"code": "D004475",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A16.504.273"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Endoderme",
"alternateName": "Endoderm",
"url": "https://questionsmedicales.fr/mesh/D004707",
"about": {
"@type": "MedicalCondition",
"name": "Endoderme",
"code": {
"@type": "MedicalCode",
"code": "D004707",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A16.504.407"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Mésoderme",
"alternateName": "Mesoderm",
"url": "https://questionsmedicales.fr/mesh/D008648",
"about": {
"@type": "MedicalCondition",
"name": "Mésoderme",
"code": {
"@type": "MedicalCode",
"code": "D008648",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A16.504.660"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Péricytes",
"alternateName": "Pericytes",
"url": "https://questionsmedicales.fr/mesh/D020286",
"about": {
"@type": "MedicalCondition",
"name": "Péricytes",
"code": {
"@type": "MedicalCode",
"code": "D020286",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A16.504.660.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Somites",
"alternateName": "Somites",
"url": "https://questionsmedicales.fr/mesh/D019170",
"about": {
"@type": "MedicalCondition",
"name": "Somites",
"code": {
"@type": "MedicalCode",
"code": "D019170",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A16.504.660.750"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Feuillets embryonnaires",
"alternateName": "Germ Layers",
"code": {
"@type": "MedicalCode",
"code": "D005855",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elizabeth R Gavis",
"url": "https://questionsmedicales.fr/author/Elizabeth%20R%20Gavis",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America."
}
},
{
"@type": "Person",
"name": "Bernard K van der Veer",
"url": "https://questionsmedicales.fr/author/Bernard%20K%20van%20der%20Veer",
"affiliation": {
"@type": "Organization",
"name": "Laboratory for Stem Cell and Developmental Epigenetics, Department of Development and Regeneration, Katholieke Universiteit Leuven, 3000 Leuven, Belgium."
}
},
{
"@type": "Person",
"name": "Kian Peng Koh",
"url": "https://questionsmedicales.fr/author/Kian%20Peng%20Koh",
"affiliation": {
"@type": "Organization",
"name": "Laboratory for Stem Cell and Developmental Epigenetics, Department of Development and Regeneration, Katholieke Universiteit Leuven, 3000 Leuven, Belgium."
}
},
{
"@type": "Person",
"name": "Ulrich Technau",
"url": "https://questionsmedicales.fr/author/Ulrich%20Technau",
"affiliation": {
"@type": "Organization",
"name": "Department for Molecular Evolution and Development, Centre of Organismal Systems Biology, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria ulrich.technau@univie.ac.at."
}
},
{
"@type": "Person",
"name": "Patrick P L Tam",
"url": "https://questionsmedicales.fr/author/Patrick%20P%20L%20Tam",
"affiliation": {
"@type": "Organization",
"name": "Embryology Research Unit, Children's Medical Research Institute, and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "DNA Methylation in the Fields of Prenatal Diagnosis and Early Detection of Cancers.",
"datePublished": "2023-07-20",
"url": "https://questionsmedicales.fr/article/37511475",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms241411715"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.",
"datePublished": "2023-03-07",
"url": "https://questionsmedicales.fr/article/36894035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.gastro.2023.02.044"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36855007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12350-023-03202-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimal age to stop prostate cancer screening and early detection.",
"datePublished": "2023-08-19",
"url": "https://questionsmedicales.fr/article/37598870",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jcpo.2023.100443"
}
},
{
"@type": "ScholarlyArticle",
"name": "Serum IgG N-glycans enable early detection and early relapse prediction of colorectal cancer.",
"datePublished": "2022-10-03",
"url": "https://questionsmedicales.fr/article/36121650",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ijc.34298"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Structures de l'embryon",
"item": "https://questionsmedicales.fr/mesh/D004628"
},
{
"@type": "ListItem",
"position": 3,
"name": "Feuillets embryonnaires",
"item": "https://questionsmedicales.fr/mesh/D005855"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Feuillets embryonnaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Feuillets embryonnaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Feuillets embryonnaires",
"description": "Comment identifier les feuillets embryonnaires ?\nQuels examens sont utilisés pour étudier les feuillets ?\nPeut-on détecter des anomalies des feuillets ?\nQuels signes indiquent des problèmes embryonnaires ?\nLes feuillets peuvent-ils être visualisés directement ?",
"url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Early+Detection+of+Cancer&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Feuillets embryonnaires",
"description": "Quels symptômes sont liés aux anomalies des feuillets ?\nLes anomalies des feuillets affectent-elles le développement ?\nComment les anomalies se manifestent-elles ?\nLes symptômes varient-ils selon le feuillet affecté ?\nLes symptômes sont-ils toujours présents à la naissance ?",
"url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Early+Detection+of+Cancer&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Feuillets embryonnaires",
"description": "Comment prévenir les anomalies des feuillets embryonnaires ?\nLe dépistage prénatal aide-t-il à prévenir les anomalies ?\nLes vaccinations sont-elles importantes pendant la grossesse ?\nLe stress maternel influence-t-il le développement embryonnaire ?\nLes antécédents familiaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Early+Detection+of+Cancer&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Feuillets embryonnaires",
"description": "Quels traitements existent pour les anomalies des feuillets ?\nPeut-on prévenir les anomalies des feuillets ?\nLes traitements sont-ils efficaces ?\nY a-t-il des traitements expérimentaux ?\nLes traitements nécessitent-ils un suivi ?",
"url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Early+Detection+of+Cancer&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Feuillets embryonnaires",
"description": "Quelles complications peuvent survenir avec des anomalies des feuillets ?\nLes complications sont-elles toujours visibles à la naissance ?\nLes anomalies des feuillets augmentent-elles le risque de maladies ?\nLes complications peuvent-elles être traitées ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Early+Detection+of+Cancer&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Feuillets embryonnaires",
"description": "Quels sont les facteurs de risque pour les anomalies des feuillets ?\nL'exposition à des toxines influence-t-elle le développement ?\nLes maladies maternelles affectent-elles le fœtus ?\nLe mode de vie maternel joue-t-il un rôle ?\nLes traitements médicaux peuvent-ils influencer le développement ?",
"url": "https://questionsmedicales.fr/mesh/D005855?mesh_terms=Early+Detection+of+Cancer&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les feuillets embryonnaires ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par l'observation des couches cellulaires lors de l'embryogenèse."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour étudier les feuillets ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échographie et l'imagerie par résonance magnétique (IRM) sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des anomalies des feuillets ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent être détectées par des tests génétiques et des échographies."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent des problèmes embryonnaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des malformations ou des retards de développement peuvent indiquer des problèmes."
}
},
{
"@type": "Question",
"name": "Les feuillets peuvent-ils être visualisés directement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils sont généralement étudiés par des méthodes indirectes comme l'imagerie."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux anomalies des feuillets ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des malformations physiques et des troubles fonctionnels."
}
},
{
"@type": "Question",
"name": "Les anomalies des feuillets affectent-elles le développement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des retards de croissance et des dysfonctionnements organiques."
}
},
{
"@type": "Question",
"name": "Comment les anomalies se manifestent-elles ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent se manifester par des malformations visibles ou des troubles internes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le feuillet affecté ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, chaque feuillet (ectoderme, mésoderme, endoderme) a des implications spécifiques."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents à la naissance ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, certaines anomalies peuvent se développer plus tard dans l'enfance."
}
},
{
"@type": "Question",
"name": "Comment prévenir les anomalies des feuillets embryonnaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'évitement de substances nocives et des soins prénatals sont cruciaux."
}
},
{
"@type": "Question",
"name": "Le dépistage prénatal aide-t-il à prévenir les anomalies ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage permet d'identifier les risques et d'agir en conséquence."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes pendant la grossesse ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations protègent le fœtus contre des infections pouvant causer des anomalies."
}
},
{
"@type": "Question",
"name": "Le stress maternel influence-t-il le développement embryonnaire ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un stress élevé peut affecter le développement et augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux d'anomalies peuvent augmenter le risque pour le fœtus."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les anomalies des feuillets ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements varient de la chirurgie corrective à la thérapie génique selon l'anomalie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les anomalies des feuillets ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent être prévenues par une bonne nutrition et des soins prénatals."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité dépend de la nature et de la gravité de l'anomalie détectée."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des recherches sont en cours sur des thérapies innovantes pour certaines anomalies."
}
},
{
"@type": "Question",
"name": "Les traitements nécessitent-ils un suivi ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour évaluer l'évolution et ajuster les soins."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des anomalies des feuillets ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des malformations graves, des troubles fonctionnels et des décès néonatals."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles toujours visibles à la naissance ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certaines complications peuvent se manifester plus tard dans l'enfance."
}
},
{
"@type": "Question",
"name": "Les anomalies des feuillets augmentent-elles le risque de maladies ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent prédisposer à des maladies chroniques ou à des troubles du développement."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être traitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées par des traitements médicaux ou chirurgicaux."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent avoir un impact significatif sur la qualité de vie de l'individu."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des feuillets ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge maternel avancé, des antécédents familiaux et des infections."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines influence-t-elle le développement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les maladies maternelles affectent-elles le fœtus ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines maladies, comme le diabète, peuvent augmenter le risque d'anomalies congénitales."
}
},
{
"@type": "Question",
"name": "Le mode de vie maternel joue-t-il un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme, l'alcool et une mauvaise nutrition sont des facteurs de risque importants."
}
},
{
"@type": "Question",
"name": "Les traitements médicaux peuvent-ils influencer le développement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent être tératogènes et affecter le développement embryonnaire."
}
}
]
}
]
}
The central objective of the metamorphosis of discovery science into biomedical applications is to serve the purpose of patients and curtail the global disease burden. The journey from the discovery o...
Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improv...
The present 3-step study incorporated data from 2141 patients, including 888 with GC, 158 with chronic atrophic gastritis, 193 with intestinal metaplasia, 501 healthy donors, and 401 with other gastro...
In discovery phase, one LR (GClnc1) was found to be up-regulated in both tissue and circulating EV samples with an area under the curve (AUC) of 0.9369 (95% confidence interval [CI], 0.9073-0.9664) fo...
EV-derived GClnc1 serves as a circulating biomarker for the early detection of GC, thus providing opportunities for curative surgery and improved survival outcomes....
Cancer therapy-induced cardiotoxicity is an emerging clinical and healthcare issue. Myocardial dysfunction and heart failure are mostly responsible for increased cardiovascular mortality in cancer dis...
Prostate Cancer screening should be discontinued at older ages because competing mortality risks eventually dominate the risk of Prostate Cancer and harms exceed benefits. We explored the Prostate Can...
We applied Bellman Equations to formulate the net benefits biopsy and "do nothing". Using difference between the net benefits of two alternatives, we calculated the stopping age. The cancer states wer...
Our results suggested that Prostate Cancer screening stopping ages from the patient, healthcare system, and social were 70, 68, and 68 respectively. The univariate sensitivity analysis showed that the...
Men should not be screened for Prostate Cancer beyond 70 years old, as this results in the net benefit of "do nothing" above the biopsy. Nevertheless, this finding needs to be further studied with mor...
Colorectal cancer (CRC) develops mainly from colorectal advanced adenomas (AA), which are considered precancerous lesions. Novel early diagnostic biomarkers are urgently needed to distinguish CRC and ...
The modality to detect ovarian cancer at an early stage is very limited. Early diagnosis determines the prognosis. This study aimed to develop a risk assessment tool for early detection of ovarian can...
This study was carried out as a cohort study of patients diagnosed with suspected ovarian tumors undergoing cytoreduction operation at Hasan Sadikin Hospital, Bandung, from December 2019 to September ...
In total, 115 patients included in this study. The differences were statistically significant in terms of the six variables (abdominal bloating, nausea/vomiting, decreased of appetite, fullness, menst...
Risk assessments based on ovarian cancer self-assessment unfortunately were not comparable to postoperative histopathology as a single predictor. Ten variables in ovarian cancer artificial intelligenc...
Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness o...
In this research, we harnessed the Mutation Capsule Plus (MCP) technology to profile an array of genomic characteristics from cfDNA procured from a single blood draw. This profiling encompassed DNA me...
This model was subsequently validated in another cohort comprising 89 CRC patients and 95 healthy controls. Remarkably, the model achieved an area under the curve (AUC) of 0.981 (95% confidence interv...
Our findings underscore the clinical potential of our multiomics liquid biopsy test, indicating its prospective role as a noninvasive method for early-stage CRC detection. This multiomics approach hol...
Clinical diagnostics rely heavily on the detection and quantification of cancer biomarkers. The rapid detection of cancer-specific biomarkers is of great importance in the early diagnosis of cancers a...
A cell-free DNA (cfDNA) assay would be a promising approach to early cancer diagnosis, especially for patients with dense tissues. Consistent cfDNA signatures have been observed for many carcinogens. ...
Hepatocellular carcinoma (HCC) is the fastest-rising and fourth most common cause of cancer death worldwide. Liver cirrhosis is the largest underlying risk factor for HCC. Therefore, patients with cir...
This is a UK-based prospective, longitudinal, diagnostic, prognostic, multicentre, non-CTIMP study. Aiming to recruit 3000 patients with liver cirrhosis without a HCC diagnosis, the Pearl cohort will ...
Ethical approval has been granted by REC and the trial is registered on ClinicalTrials.gov. The results will be published in peer-reviewed journals and presented at relevant meetings....
NCT05541601....